Challenge your diagnostic skills! • Patient presentation: Abdominal pain, purpura, hematuria • History: Cryoglobulinemia, kidney injury • Exam: Purpura, tenderness • Lab: Anemia, thrombocytopenia, elevated LDH What's your next step? Answer here: focusononcology.com/diagnostic-cha…

T-DXd is approved for the treatment of patients with ANY treatment-refractory HER2+ (IHC 3+) tumor, making of it the first agnostic ADC. Unlikely to be the last. Key priority: ensuring that HER2 testing is expanded across cancer types. Exciting times! fda.gov/drugs/resource…

20 PGY 1 positions opened up in Texas! Great opportunity for those that don’t require visa!!

#Alectinib now FDA Oncology approved based off #ALINA trial. Alectinib vs Chemo post resection in NSCLC, Stg Ib-IIIA: - Alectinib for 2 yrs - Improved DFS in all subgroups: HR0.24 - Improved CNS DFS HR: 0.22 - New Soc Ben Solomon #lcsm #onctwitter #medtwitter

In patients with node-positive breast cancer, axillary recurrence after omission of axillary lymph node dissection was rare with no difference by type of surgery (sentinel lymph node biopsy with dual-tracer mapping vs targeted axillary dissection). ja.ma/3We973M

Early measurement allows the identification of patients with low DOAC levels and treatment adjustment to avoid future thrombotic events. ow.ly/eSjX50Rms0T #clinicaltrialsandobservations #thrombosisandhemostasis

For our stellar med students on Oncology rotations!! Very crucial advice

< 2 weeks to #ASCO24, here is a📝 of 🔑abstracts for general onc that could guide our SoC! - #ESOPEC - #COMMIT - #INAVO120 - #DestinyBreast06 - #LAURA - #ADRIATIC - #NADINA - #MARIPOSA - #Amyloidosis #BCSM #GISM #LCSM #MedTwitter #GUSM #OncTwitter ASCO OncoAlert

👉👉As we are increasingly using NGS MRD (10-6 sensitivity) vs. flow (10-4 sensitivity) such as in B-ALL, here is a brief summary slide with some general concepts about assay depth, and blood vs marrow as sample source Welcome additional thoughts and comments.

Thrilled to complete the year-long FLIGHT professional development program by UofL School of Medicine! This initiative supports the growth and success of underrepresented minorities in medicine. Proud to be part of this community! #MedTwitter #DiversityInMedicine University of Louisville

Amivantamab subcutaneous vs intravenous in combination with Lazertinib improves safety and tolerability in 3rd line EGFR+ NSCLC. Honored to participate in PALOMA 3 trial on behalf GVADptoSaludAlicante Oncology Team member of ISABIAL. Presented at #ASCO24 #lcsm OncoAlert

Great panel discussion by Rahul Gosain Oncology Brothers, Megan Emmich, DO, and Eleonora Teplinsky, MD, FASCO on the career path in Community Oncology at ASCO TECAG ASCO #ASCO24

Second chance to #palbociclib in #inavo120 Can friends help palbo? Let’s see inavolisib plus fulvestrant and palbociclib combination #ASCO24 OncoAlert

Re: #INAVO-120 do you foresee hesitation adopting this regimen given Palbo did not show OS benefit in first line setting? Particularly until OS data available for combination Fulvestrant + palbo + inavolisib #ASCO24 #bcsm

👏🏼 for #LAURA Osimertinib vs placebo after chemo-RT unresectable stage 3 NSCLC w/ EGFR exon19del 🌀prior SOC is adj Durva #PACIFIC but those w/ EGFRm have ⬇️ efficacy 🌟PFS HR 0.16, 39.1mo vs 5.6mo 🌀OS not mature/significant HR 0.81 w/ 81% cross over from control #ASCO24

Standing ovation for the practice changing LAURA trial ⁦ASCO⁩ #ASCO24 ⁦OncoAlert⁩ ⁦Hem-Onc Fellows Network⁩ ⁦Heme/Onc Fellows UofL⁩

ADRIATIC trial for L-SCLC ASCO #ASCO24 Consolidation durvalumab - new standard of care for patients who have not progressed on cCRT Heme/Onc Fellows UofL Hem-Onc Fellows Network OncoAlert

The #OncoAlertTopTweet 🚨Day 3 #ASCO24 by Arndt Vogel Perioperative CT (FLOT) vs. neoadjuvant CT-RT (CROSS) in patients with adenocarcinoma of the oesophagus - the ESOPEC trial #OncoAlertAF Dra. María Natalia Gandur Quiroga Alizée Camps - - Maléa Marta Perachino Kathrin Heinrich Biagio Ricciuti, MD PhD

We’ve issued a rapid guideline update on systemic therapy for #sclc. These recommendations are considered provisional pending full text review of publication and confirmation of data. ➡️ brnw.ch/21wKD3i #lungcancer #lcsm

Extravasation management of vesicant and irritant agents👇 OncoAlert